Redmile Group, LLC Fate Therapeutics Inc Transaction History
Redmile Group, LLC
- $1.28 Billion
- Q4 2024
A detailed history of Redmile Group, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Redmile Group, LLC holds 12,872,946 shares of FATE stock, worth $19.7 Million. This represents 1.66% of its overall portfolio holdings.
Number of Shares
12,872,946
Previous 13,169,057
2.25%
Holding current value
$19.7 Million
Previous $46.1 Million
53.92%
% of portfolio
1.66%
Previous 3.01%
Shares
13 transactions
Others Institutions Holding FATE
# of Institutions
166Shares Held
101MCall Options Held
41.3KPut Options Held
15.9K-
Vanguard Group Inc Valley Forge, PA10.3MShares$15.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$15.5 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$7.4 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$6.7 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.56MShares$5.44 Million0.15% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $148M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...